Table 5.
ART (n = 65) | Planned (n = 201) | Unplanned (n = 23) | Pa | Pb | Pc | Pd | |
---|---|---|---|---|---|---|---|
Outcomes | |||||||
Time of delivery, weeks, mean ± SD | 36.8 ± 2.1 | 37.1 ± 2.0 | 34.8 ± 3.1 | < 0.001 | 0.267 | 0.001 | < 0.001 |
Birth weight, mean ± SD | 2653.5 ± 578.6 | 2703.3 ± 491.3 | 2298.3 ± 762.5 | 0.003 | 0.498 | 0.023 | 0.001 |
IUGR, n (%) | 5 (7.7) | 17 (8.5) | 4 (17.4) | 0.383 | |||
Fetal distress, n (%) | 5 (7.7) | 32 (15.9) | 3 (13.0) | 0.233 | |||
LBW infants, n (%) | 20 (30.8) | 51 (25.4) | 7 (30.4) | 0.641 | |||
VLBW infants, n (%) | 2 (3.1) | 5 (2.5) | 5 (21.7) | 0.001 | 0.680 | 0.012 | 0.001 |
Neonatal hypoglycemia, n (%) | 2 (3.1) | 2 (1.0) | 1 (4.3) | 0.188 | |||
Neonatal pneumonia, n (%) | 3 (4.6) | 3 (1.5) | 1 (4.3) | 0.702 | |||
NRDS, n (%) | 5 (7.7) | 7 (3.5) | 1 (4.3) | 0.621 | |||
Neonatal pathological jaundice, n (%) | 11 (16.9) | 29 (14.4) | 2 (8.7) | 0.702 | |||
Malformation, n (%) | 6 (9.2) | 12 (6.0) | 1 (4.3) | 0.621 | |||
PDA, n (%) | 2 (3.1) | 9 (4.5) | 2 (8.7) | 0.501 | |||
PFO, n (%) | 7 (10.8) | 24 (11.9) | 1 (4.3) | 0.707 | |||
ASD, n (%) | 4 (6.2) | 5 (2.5) | 1 (4.3) | 0.280 | |||
Transfer to ICU, n (%) | 10 (15.4) | 70 (34.8) | 8 (34.8) | 0.011 | 0.003 | 0.070 | 1.000 |
Laboratory tests | |||||||
ANA, n (%) | 12 (18.5) | 24 (11.9) | 4 (17.4) | 0.313 | |||
Anti-dsDNA, n (%) | 5 (7.7) | 11 (5.5) | 3 (13.0) | 0.244 | |||
Anti-SSA, n (%) | 6 (9.2) | 12 (6.0) | 3 (13.0) | 0.265 | |||
Anti-SSB, n (%) | 2 (3.1) | 0 (0) | 1 (4.3) | 0.028 | 0.059 | 1.000 | 0.103 |
Abbreviation: ART Assisted reproductive therapy, ASD Atrial septal defect, ICU Intensive care unit, LBW Low-birth-weight, IUGR Intrauterine growth retardation, NRDS Neonatal respiratory distress syndrome, PDA Patent ductus arteriosus, PFO Patent foramen ovale, SD Standard deviation, VLBW Very-low-birth-weight